Overview

Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase

Status:
NOT_YET_RECRUITING

Trial end date:
2027-06-30

Target enrollment:

Participant gender:

Summary

This study is a prospective, randomized, parallel-controlled clinical trial, aiming to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to standard treatment alone as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) in both the pre-cachexia and cachexia phases. Participants enrolled in the study are those with ES-SCLC in the pre-cachexia or cachexia phase who have not received systemic treatment and are not eligible for curative therapy.

Phase:

PHASE3

Details

Lead Sponsor:

Changchun GeneScience Pharmaceutical Co., Ltd.

Collaborator:

West China Hospital